Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes

Lancet Oncol. 2018 Jan;19(1):23-24. doi: 10.1016/S1470-2045(17)30916-6.

Authors

Michael Cecchini¹, Zenta Walther², Jeffrey L Sklar², Ranjit S Bindra³, Daniel P Petrylak¹, Joseph P Eder¹, Sarah B Goldberg⁴

Affiliations

¹ Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
² Department of Pathology, Yale School of Medicine, New Haven, CT, USA.
³ Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA.
⁴ Department of Medicine, Medical Oncology, Yale School of Medicine, New Haven, CT, USA. Electronic address: [email protected].

PMID: 29304353
DOI: 10.1016/S1470-2045(17)30916-6

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Ataxia Telangiectasia Mutated Proteins / genetics
Biomarkers, Tumor / genetics
Disease Progression
Fatal Outcome
Humans
Male
Middle Aged
Molecular Targeted Therapy*
Mutation
Phthalazines / therapeutic use*
Piperazines / therapeutic use*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
Precision Medicine
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / genetics
Prostatic Neoplasms / secondary
Sarcoma / drug therapy*
Sarcoma / genetics
Sarcoma / secondary
Treatment Outcome

Substances

Biomarkers, Tumor
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
ATM protein, human
Ataxia Telangiectasia Mutated Proteins
olaparib